has been lengthened to a mere 8%. 1 By 2030, the number of deaths from pancreatic cancer will surpass breast, prostate, and colon cancer and become the second leading cause of death by cancer in the United States. 2 In 2016, data from the ESPAC-4 trial was released comparing gemcitabine alone to gemcitabine plus capecitabine in the adjuvant post-resection setting, improving survival from 25.5 months to 28 months. 3 Unfortunately, 80% of patients present with locally advanced (unresectable) or metastatic disease.
The standard of care first line systemic therapy options for metastatic disease include gemcitabine alone, gemcitabine with nab-paclitaxel, or FOLFIRINOX with a respective median survival of 6, 8, and 11.1 months. The choice of regimen is dictated by the patients' performance status. 4, 5 The majority of patients both treated with resection and chemotherapy or chemotherapy alone eventually succumb to the disease. There remains a great deal to be accomplished in improving outcomes.
There are inherent unique characteristics of pancreatic ductal adenocarcinoma (PDAC) that have made it particularly challenging to treat. Limitations in the management of PDAC include: (1) the lack of early detection modalities; (2) the occult nature of progression where patients at presentation have disseminated disease; and (3) the presence of an exacerbated desmoplastic response that severely compromises tumor blood perfusion and drug delivery while imposing pressure for selection, further enabling the emergence of drugresistant malignant clones. [6] [7] [8] [9] The desmoplastic microenvironment within the tumor is comprised of a complex dynamic milieu that both enables and contains the tumor. As more work is being done on this complex tumor-stroma relationship, the biology of PDAC is being further elucidated. The content of this review will focus on delineating these critical stromal components and how they may be utilized as therapeutic targets (Table 1 ).
| The unique microenvironment of pancreatic cancer
The microenvironment in pancreatic cancer is comprised of acellular stroma, cancer associated fibroblasts (CAF, also known as pancreas stellate cells [PSC] ), immune cells, and soluble factors such as cytokines, chemokines, growth, and pro-angiogenic factors (Fig. 1 ). The interaction of the stroma and tumor cells has best been studied extensively in the context of the molecular and cellular evolution of PDAC. The eventual development of PDAC is thought to stem from acinar ductal metaplasia (ADM), and subsequent morphologic changes of pancreatic intra-event in greater than 90% of PDAC. 13 Additional subsequent somatic mutations in tumor suppressor genes include p16, p53, and DPC/SMAD4
which cumulatively lead to progressive epithelial transformation from PanIN1-3 and ultimately PDAC capable of metastasizing to lymph nodes and distant organs. [14] [15] [16] 
| Tumor-associated macrophages (TAM)
TAMs reside within the TME in PDAC and are thought to serve as a potential therapeutic target in several solid tumors. 50 There was a recent Phase II trial in PDAC targeting TAMs with the cytotoxic agent trabectedin (NCT01339754). 45, 51 Trabectedin targets mononuclear phagocytes selectively via caspase-8 dependent apoptosis and via differential expression of signaling and decoy TRAIL receptors in macrophages. TAMs have also had a role in PDAC progression via production of IL-6 and activation of the STAT3 pathway. 10, 52 Upon recruitment and activation, TAMS release IL-6 and thus activate the STAT3/SOCS pathway. This accelerates PDAC generation.
| Myeloid cell infiltration and polymorphonuclear neutrophils (PMN)
There is mounting evidence that infiltrating immune cells in the PDAC microenvironment are pro-tumorigenic. 53 These cells are found early in the development of PDAC and can be found surrounding early PanIN I lesions. 42 Local tumor derived production of granulocyte macrophage colony-stimulating factor (GM-CSF) recruits myeloid progenitor cells and induces subsequent differentiation of these into myeloid-derived suppressor cells (MDSCs). 54 MDSCs in turn function to mitigate the CD8+ killer T cell immune surveillance functions. This prevents tumor-specific cytotoxic T cells from clearing transformed pancreatic ductal cells. 55 Targeted depletion of granulocytic MDSC (Gr-MDSC) activates an endogenous antitumor T cell response indicating perhaps Gr-MDSC may be a promising therapeutic target in PDAC. 56 In PDAC, the presence of TANs is associated with poor clinical outcome. 57 PMN infiltrates can be observed near tumor cells or in the stroma and are associated with poor differentiation. 58 HA is a glycosaminoglycan that is found in abundance in the PDAC TME. The fibrotic collagens and HA contribute to the ECM component of PDAC thus creating the desmoplasia that is so characteristic of these tumors. 9 The desmoplasia and elevated interstitial fluid pressure (IFP) contribute to the barriers in the delivery of systemic therapies to this tumor by compressing/collapsing the tumor blood vessels. 76 HA contributes to this IFP and functions as a core polymer whereby multiple hydrophilic matrix proteoglycans are formed. This allows for a gel like matrix that supports tumor growth and retains growth factors and cytokines. 77 Functionally HA also binds to the CD44 and RHAMM cell surface receptors. This activates signaling pathways that contribute to cell invasion, migration, proliferation, adhesion, and survival. 78 Based on these roles, HA has been identified as a target to enhance delivery of therapeutics. 79, 80 PEGPH20 is a PEGylated recombinant hyaluronidase that degrades HA and has been found in both animal and human studies to transiently enhance penetration of systemic chemotherapy. In a Phase I/II clinical trial, gemcitabine when combined with PEGPH20 improved both overall survival and progression-free survival in advanced PDAC (NCT01453153). These findings were even more pronounced with patients that had high levels of HA expression. The limitations of this therapy include thromboembolic events and therefore, anticoagulation is now administered in conjunction with PEGPH20 in active clinical trials (combination of PEGPH20/gemcitabine/nab-paclitaxel-NCT02715804
and PEGPH20 and FOLFIRINOX-NCT01959139).
| Hedgehog inhibitors
Targeting the stromal components has not always been a success. The
Hedgehog pathway is hyperactivated in PDAC and is known to stimulate PSC's to regulate stromal production. 81 shown to improve gemcitabine perfusion and survival. 81 Unfortunately, clinical trials targeting this pathway were subject to early termination secondary to progression. There have been several proposed explanations for this lack of success. First, as predicted, depletion of the prostromal Shh pathway leads to fewer myofibroblasts and tumor stroma.
However, there were more frequent ADM and PanIN lesions during early carcinogenesis and established tumors were undifferentiated, more likely to metastasize and with a higher proliferative index compared to littermates. 83 Second, there is increased tumor vasculature and reduced autophagy. 45 Lastly it has been postulated that with regards to gemcitabine chemotherapy, there is a transporter hENT1 and an activating enzyme deoxycytidine kinase that are associated with improved survival. 84, 85 This suggests that gemcitabine metabolism rather than biophysical delivery may matter more. Perhaps the stroma is contributing to some tumor control and therefore, permanent stroma depletion leads to more aggressive disease.
This explanation has yet to be clearly elucidated but the disappointing findings of trials targeting the Hh pathway indicate that clearly the stroma may have a tumor insulating role.
| Connective tissue growth factor (CTGF)
CTGF is a pro-fibrotic mediator that is found in abundance in the stroma of PDAC and is the target of an ongoing trial (NCT02606136). 86 Over expression of CTGF is regulated by chemokine signaling through CXC proteins which bind integrins and growth factors to promote fibrosis and collagen deposition, and subsequently cancer progression and metastasis. 87, 88 In preclinical models the monoclonal antibody FG-3019 resulted in higher rates of tumor cell apoptosis when combined with gemcitabine. Interestingly, the gross appearance of the cellular and acellular tumor stroma was unchanged.
In contrast, there was significant molecular down regulation of prosurvival and anti-apoptotic proteins such as hypoxia inducible factor1alpha (HIF1-α), Psen1, Ubqln2, Birc6, X-linked inhibitor of apoptosis (XIAP). 45 In a recent Phase I trial, the human monoclonal antibody against CTGF (FG-3019) was tested with gemcitabine and erlotinib in Stage 3 or 4 pancreatic adenocarcinoma. Results were that with a high exposure (at least 15 days of treatment) and low baseline CTGF plasma levels there was improved PFS and OS. Currently there is an ongoing Phase I/II trial of gemcitabine and nab-paclitaxel with our without FG-3019 (pamrevilumab) in the neoadjuvant setting for locally advanced pancreatic cancer (NCT02210559).
| Angiotensin inhibitors
There is currently a clinical trial investigating the combination of 
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This compound has yet to be evaluated in human trials.
| Angiogenesis
In the PDAC TME there is angiogenesis in response to chronic hypoxia, however, the vessels appear compressed secondary in part to the abundance of extracellular matrix proteins. There has been work in designing a hypoxia-activated prodrug TH-302 that improved progression free survival of mice and is currently in Phase II/III clinical trials in advanced PDAC patients (NCT-01746979). Additionally the most well studied inhibitor of angiogenesis (Bevacizumuab; anti-VEGF antibody) when studied in pancreatic cancer patients did not translate into significant benefits in survival. 101 Unlike its common use in metastatic colorectal cancer, bevacizumab has not materialized as the standard of care for PDAC.
Additional targets of angiogenesis in pancreas cancer have been the hepatocyte growth factor (HGF)-c-MET pathway. In the TME, PSC's secrete HGF which binds to cMET on pancreatic cancer cells.
This binding leads to cMET receptor phosphorylation and downstream signaling, inducing PDAC cell growth, and migration. Blockage of HGF has been found to decrease angiogenesis. This may be a target of future investigation. CD40 is an additional target that has been evaluated as it may have a role in T cell dependent and independent immune mediated mechanisms of tumor regression. CD40 is cell surface molecule and as a member of the TNF receptor family, partakes in immune regulation, and tumor apoptosis. 109 CD40 was initially thought to be crucial in T cell dependent anti-tumor; immunity, however, more recently it is thought that CD40 mediated tumor regression is more dependent on macrophages that facilitate stroma depletion. In a phase I trial, patients with advanced PDAC were treated with a monoclonal antibody that is a CD40 agonist (CP-870). 110 Of the 22 patients, four (18%) achieved a partial response and in those tumors, there was a significant population of macrophages and minimal tumor infiltrating lymphocytes.
| Immunotherapy and the tumor microenvironment
Both programmed cell death-1 receptor (PD-1) and PD-1 ligand expression are associated with poor prognosis. The expression of these, suppresses T cell activity and allows for immune escape in the TME. However, early clinical trials targeting either PD-1 or PD-L1 did not demonstrate a significant response as monotherapy for PDAC. 111, 112 There are currently several trials underway utilizing combination therapies with targeted therapies to PD-1 or PD-1 ligands.
| Secreted protein acid and rich in cysteine (SPARC)
SPARC is over expressed in the PDAC TME and is associated with promoting tumor invasion and inhibiting angiogenesis. 113 An additional strategy to better deliver therapeutics to PDAC is to modify chemotherapeutic agents such that the affinity for endogenous stromal receptors is increased. With this in mind, paclitaxel was conjugated with albumin-nanoparticles (nab-paclitaxel) with the hopes of better efficacy via albumin mediated absorption and binding by SPARC. However, the levels of SPARC expression did not appear to correlate with response to treatment. 114, 115 Additionally, there is work citing that the efficacy of nab-paclitaxel is actually dependent upon drug internalization by TAMs via macropinocytosis. 116 Therefore, 
